Boehringer partnership to advance biologic for rare skin condition

Boehringer Ingelheim and LEO Pharma have agreed a partnership deal to advance development and commercialisation of the innovative monoclonal antibody Spevigo® (spesolimab).

It is the first drug approved for generalised pustular psoriasis flares that specifically targets the IL-36 pathway. It is a rare and potentially life-threatening skin disease, the companies shared.